Overview

A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy

Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study will examine the efficacy, safety, and effect on hemoglobin levels, of once weekly epoetin beta subcutaneous injections (30,000 International Units [IU]) in anemic patients with solid tumors. The anticipated study duration is 4 months, and the target sample size is 40 individuals.
Phase:
Phase 4
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Epoetin Alfa